Recombinant protein production
The company says target proteins can be expressed in silkworms in less than a week, and production is scaled by increasing the number of silkworms.
Source: LinkedIn company description · Retrieved October 13, 2026
KAICO is a Japanese biotechnology start-up focused on developing and producing recombinant proteins using a silkworm-baculovirus expression system.
KAICO uses silkworms as bioreactors to express recombinant proteins that are difficult to extract using systems such as microbes and cells. Its current development programs include oral vaccines for humans and animals.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company says target proteins can be expressed in silkworms in less than a week, and production is scaled by increasing the number of silkworms.
Source: LinkedIn company description · Retrieved October 13, 2026
KAICO’s current development programs include oral vaccines for human and animal use.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026 and September 18, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.